Address: Bodenhof 4, 6014 Lucerne, Switzerland
CBC Health AG - REGENERATIVE TREATMENT FOR ISCHEMIC STROKE
  • 0 Patiens

CBC Health is providing innovative cord blood infusions for individuals across the globe who have had an ischemic stroke.

Currently, we may be the only clinic providing this treatment. Other institutions and universities are conducting clinical trials on the topic. We have 20 years’ experience with cord blood banking storing around 200 000 CBU.

Ischemic stroke patients treated by CBC Health may benefit from regenerative improvements in the brain that can include:

Neurotrophic Influence - Immune Benefits - Inflammation Reduction

Cord blood cells treatment has been studied in several clinical trials on patients with brain impairment caused by ischemic stroke. All have shown significant improvement.

Important facts about Cord Blood infusion treatment

Moderate improvement in motoric and cognitive functions after the treatment is highly probable, based on published results of clinical studies. These clinical studies have been conducted on patients with cerebral palsy and stroke.

Risks of cord blood infusion are very low, well known and transparent. They are comparable to the risks of blood cells transfusion.

Some patients experience higher improvement and others lower.

Although we are currently only located in Munich, Germany, we are accustomed to accommodating patients from all over the world with the help of our Medical Concierge. We provide assistance throughout the whole process of getting to and from the treatment in Munich.

Umbilical cord blood cell infusion for stroke treatment

Overview

Intravenous infusion of umbilical blood cells is a therapeutic procedure used in patients recovering from stroke.

Umbilical cord blood is collected from placenta via the umbilical cord vein.

To achieve an optimum therapeutic effect, a dose of 50 million cells per kg is required, and each infusion includes cord blood collected from 4 to 8 donors.

The entire course of infusions is scheduled over two to three days, and after each infusion, the patient is monitored for several hours for any potential adverse reactions.

In the majority of patients, cord blood infusions have resulted in mild improvement of cognitive and motor functions.  These functional gains become noticeable within the first few weeks after the infusion and continue for the next 3 to 6 months.

Adverse reactions to cord blood cell infusions are rare and generally mild.

The treatment effect

Cord blood infusion is not intended to be a replacement for standard therapy in the management of stroke, it is additional therapeutic approach that may gain additional improvement of cognitive and motor functions.

In patients undergoing cord blood therapy, there no need to temporarily discontinue other types of pharmaceutical or physical therapy.

Intravenous cord blood cell infusions enhance the regenerative activity of brain cells in stroke patients.

Clinical studies suggest that cord blood therapy is more effective when administrated soon after stroke occurs.

Patients begin to notice improvements within a few weeks after the infusion.  The cord blood cells are eliminated from the patient’s body within 6 to 8 weeks; however, patients experience functional gains over the next 3 to 6 months, with sustained functional improvement.  Achieved improvement is permanent, patients do not experience worsening of the achieved improvement.

Patients with severe functional impairment may experience little or no improvement, and patients  with mild or minimal impairment experience moderate improvement.

Clinical studies have shown that the most important factor influencing the therapeutic effect of cord blood infusion is cell dosage.  In a recent clinical trial at Duke University on pediatric cerebral palsy patients (mostly induced by stroke), only patients who received more than 25 million cells per kg showed significant therapeutic effect (Kurtzberg et al; Blood 2015). In each of our cord blood infusions, the patient receives a standard of more than 50 million cells per kg.

Another study suggests that repeated cord blood infusions may lead to further functional improvements.

The treatment procedure 

The cord blood infusion procedure involves the intravenous infusion of donated cord blood cells.  The procedure differs from standard blood transfusions with regard to the source of blood cells.

Umbilical cord blood is the blood that remains in the placenta after the newborn’s umbilical cord has been clamped and cut.  Collection of cord blood from the placenta is harmless and painless for child and mother. The residual placenta and umbilical blood or “cord blood” is collected via the umbilical vein.  When cord blood is not collected, it is discarded with the placenta.

Each single donor cord blood collection is designated as a Cord Blood Unit (CBU).  Cord blood units are stored in liquid nitrogen at approximately -200°C (-320°F).

In order to maximize therapeutic effect, a dose of greater than 50 million cord blood cells per kg from 4 to 8 donors is infused in each procedure, and the cord blood infusions are generally administered over the course of 2 to 3 days.

Before the procedure

Consultations

In the initial phone or video consultation, our physicians collect a comprehensive medical history, provide detailed information about the procedure and address any unanswered questions.

Based on the initial evaluation, the consulting physician will determine if you are eligible for the procedure and if any additional diagnostic procedures and tests will be necessary prior to treatment. Based on your weight and blood group, cord blood units will be preselected and reserved for your treatment.

Examination

On the first day in our clinic, a number of preliminary tests need to be completed. Blood group determination must be completed if previously unknown.  Standard biochemical tests will be performed for assessment of kidney function and an echocardiogram (EKG/ECG) will be performed to assess cardiac function. If results will show abnormalities, additional diagnostics may be done.

After the preliminary interview, examination, and baseline testing, the treating physician will propose a final treatment plan.

During the procedure

Every Cord Blood Unit (CBU) is double-checked to ensure patient compatibility.

Each patient’s treatment plan is different.  After the nurse establishes intravenous access, and infusions may last from 20 minutes to 2 hours, depending on how many units are infused.

During and after each infusion, patients are attended by doctors and medical staff to monitor for any potential adverse reactions.

After a final examination by the treating physician, you will be released from the clinic. One side effect of treatment is a somewhat fishy odor on your breath for the next 24 hours. The fishy odor is caused by small amounts of dimethyl sulfoxide, a cytoprotective agent used in cryopreservation, diffusing into the lungs from the blood.

On a next day, you will return to clinic for additional infusions according to scheduled treatment plan.

After the procedure

Following the last infusion, there will be one final check-up with the treating physician.  After completion of therapy, your doctor will be in contact over the next 6 months to monitor treatment effectiveness and any potential adverse effects.

 

 

get a request


Services

  • video consultation 100 €

Additional services

VIDEO CONSULTATION

video consultation100 €


Our Location

Address: Bodenhof 4, 6014 Lucerne, Switzerland

Patient reviews on the hospital
0

0 patient reviews

Need help?

Get a free consultation by phone

By requesting a callback you agree and accept our Privacy Policy

Our Suggestions